iabetic patients are at higher risk for adverse events after percutaneous coronary intervention (PCI) compared with patients without diabetes mellitus.
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without diabetes mellitus. As consequence, the optimal device for this population remains to be determined. 4 Biodegradable polymer DES (BP-DES) were conceived to overcome the safety issues of early generation durable polymer DES (DP-DES). Polymer remnants within the arterial wall may impair vascular healing and be responsible for longterm adverse events, such as late stent thrombosis and delayed restenosis. 5 The potential advantage of BP-DES translated into similar long-term clinical outcomes and a more favorable safety profile compared with early generation DP-sirolimuseluting stents in patients with diabetes mellitus. 6 The continued progress of coronary stent technology combines an ultrathin strut cobalt-chromium platform with a biodegradable poly-l-lactic acid polymer-eluting sirolimus. The novel BP sirolimus-eluting stent (BP-SES) matched clinical performance of DP-EES, the contemporary benchmark for PCI, in the randomized Ultrathin Strut Biodegradable Polymer Sirolimus-Eluting Stent Versus Durable Polymer EverolimusEluting Stent for Percutaneous Coronary Revascularisation (BIOSCIENCE) trial. 7 We performed a prespecified subanalysis of the BIOSCIENCE trial to evaluate the performance of the ultrathin strut BP-SES compared with the thin strut DP-EES in patients undergoing PCI, according to diabetic status.
Methods

Study Design and Study Population
All patients with insulin-requiring or noninsulin-requiring diabetes mellitus enrolled in the BIOSCIENCE trial were included into the present analysis. Details of the main study and its inclusion and exclusion criteria have been previously described. 7 Briefly, BIOSCIENCE is an investigator-initiated, prospective, multicenter, single-blind, noninferiority trial comparing BP-SES with DP-EES in a patient population with minimal exclusion criteria. Patients with coronary artery disease and at least 1 lesion with a diameter stenosis >50% (de novo or restenosis) in a native vessel or in bypass graft were eligible for inclusion. After diagnostic coronary angiography, patients were randomly allocated in a 1:1 ratio to treatment with BP-SES or DP-EES. There were no restrictions to the number of treated lesions, number of vessels, or lesion length. The prespecified primary end point target lesion failure was a composite of cardiac death, targetvessel myocardial infarction, and clinically indicated target lesion revascularization (TLR) within 12 months. The study complied with the declaration of Helsinki and was funded by Biotronik, Bülach, Switzerland. The research ethics committee of each participating institution approved the protocol, and all enrolled patients provided written informed consent before inclusion. The funding source had no role in the study design, data collection, data monitoring, data analysis, or data interpretation.
Study Devices and Procedures
BP-SES (Orsiro, Biotronik AG, Bülach, Switzerland) consists of an ultrathin strut (60 μm for stent diameters ≤3.0 mm and 80 μm for stent diameters >3.0 mm) cobalt-chromium L605 platform and is coated with both a passive silicon carbide layer and a biodegradable poly-l-lactic acid polymer loaded with sirolimus at a dose of 1.4 μg/ mm 2 of stent surface. The silicon carbide coating acts as a diffusion barrier by reducing the interaction between tissue or blood with the metallic surface of the stent (passive silicon carbide layer) once the poly-l-lactic acid has been completely degraded. DP-EES (Xience Prime/Xpedition, Abbott Vascular, IL), has a thin strut (81 μm) cobalt-chromium metallic carrier and elutes everolimus from a durable polymer. Randomization was performed using a web-based system and stratified according to the center and to the presence or absence of ST-segment-elevation myocardial infarction. PCI was performed in accordance with current guidelines. Intraprocedural medications included unfractionated heparin (with a dose of 5000 IU or 70-100 IU/kg of body weight) or bivalirudin. Glycoprotein IIb/ IIIa inhibitors were administrated according to the discretion of the operator. Dual antiplatelet therapy was started before or at the time of PCI and consisted of acetylsalicylic acid (>250 mg) in combination with clopidogrel (loading dose, 600 mg; maintenance dose, 75 mg QD), prasugrel (loading dose, 60 mg; maintenance dose, 10 mg QD), or ticagrelor (loading dose, 180 mg; maintenance dose, 90 mg BID) for the recommended duration of 12 months.
Definitions and Data Management
All patients with insulin-dependent and noninsulin-dependent diabetes mellitus, as well as diabetes mellitus under diet control, were considered for the present analysis. Definitions of study outcomes have been previously described. 7 The prespecified primary end point target lesion failure was a composite of cardiac death, target-vessel myocardial infarction, or clinically indicated TLR within 12 months. Cardiac death was considered as any death because of immediate cardiac cause, deaths related to the procedure, unwitnessed death, and death of unknown cause. Myocardial infarction was defined as Q wave and non-Q wave according to the electrocardiographic criteria of the Minnesota code manual. 8 Spontaneous myocardial infarction included a typical rise and fall of creatine kinase (CK) MB fraction or troponin plus one of the following conditions: ischemic symptoms, new pathological Q waves, ischemic electrocardiographic changes, or pathological evidence of acute myocardial infarction. 9 The diagnosis of periprocedural myocardial infarction was established whenever a >50% increase of peak CK (or CK-MB isoenzyme) level above the previous level measured within 24 hours after the event was detected. 10, 11 A reinfarction was diagnosed in the case of new elevation of CK >2× the upper limit of normal if the CK had returned to normal after the index infarction or a rise by >50% above the previous nadir level if the CK level had not returned less than the upper limit of normal. TLR was considered as any repeat percutaneous or surgical intervention because of a stenosis within the stent or within the 5-mm borders proximal or distal to the stent. Target-vessel revascularization was defined as any revascularization within the major coronary vessels proximal or distal to a target lesion including side branches and target
WHAT IS KNOWN
• Next generation drug-eluting stents with biodegradable polymers were developed to improve arterial healing.
• A novel biodegradable polymer sirolimus-eluting stent has been shown to be as safe and effective as a next generation nonerodible polymer-based everolimus-eluting stent.
• Diabetic patients undergoing coronary stenting experience higher rates of adverse events when compared with nondiabetic subjects.
WHAT THE STUDY ADDS
• Diabetic status continues to negatively affect the performance of new-generation drug-eluting stents with significantly higher rates of adverse cardiovascular events compared with nondiabetic patients.
• A biodegradable polymer sirolimus-eluting stent shows a similar efficacy and safety profile as the new generation nonerodible polymer-based everolimuseluting stent in this high-risk population. BP-SES vs DP-EES in Diabetes Mellitus lesion itself. A clinically guided revascularization was considered in the presence of a stenosis of at least 50% of the lumen diameter and signs or symptoms of ischemia or if the diameter stenosis was at least 70% of the lumen diameter irrespective of the presence of signs or symptoms of ischemia. Stent thrombosis (ST) was defined according to Academic Research Consortium criteria. 12 All data were entered into a dedicated web database (Cardiobase, Clinical Trials Unit and Department of Cardiology, Bern University Hospital, Switzerland, and 2 mT, Ulm, Germany). Clinical followup was performed at 30 days and 12 months. Electrocardiographic assessment was performed at baseline, after the procedure, and at 12 months of follow-up and if signs or symptoms of ischemia occurred. Data monitoring and adverse event adjudication procedures have been described previously. 7 
Statistical Analysis
All analyses of end points were performed according to the intentto-treat principle. Clinical outcomes were compared according to diabetic status and stent type (BP-SES or DP-EES). We used time to first event for each type of outcome throughout (censoring at 365 days of follow-up) and report Kaplan-Meier estimates of event rates. Hazard ratios (HRs) were calculated using Cox regressions and reported with 2-sided 95% confidence intervals (CIs) with 2-sided P values from χ 2 tests. The interaction between diabetic status and stent type was tested using Cox regressions. Adjusted HRs were calculated including adjustment for age and sex. P values for baseline characteristics recorded at the patient level were calculated with unpaired t tests, χ 2 tests, or Fisher exact tests, except when specified. P values for baseline characteristics that were recorded at the lesion level were calculated with general or generalized linear mixed models to account for the nonindependence of lesions within the same patient. The interaction between diabetic status and randomized stent was tested with logistic regressions or general linear models for baseline characteristics. Note that P values and interaction P values of baseline characteristics are reported for explorative purposes only.
All P values and CIs are reported 2-sided. Analyses were performed with Stata 13.1 (StataCorp LP, College Station, TX).
Results
Baseline and Angiographic Characteristics
Between February 2012 and May 2013, a total of 2119 patients were enrolled in the BIOSCIENCE trial. Among the 486 (22.9%) included patients with a diagnosis of diabetes mellitus, 257 patients with 396 lesions were randomized to treatment with BP-SES and 229 patients with 331 lesions were allocated to Figure 1 . Patient flow according to the CONSORT statement. BMS indicates bare-metal stents; BP-SES, biodegradable polymer sirolimus-eluting stents; CABG, coronary artery bypass grafting; DP-EES, durable polymer everolimus-eluting stents; PCI, percutaneous coronary intervention; and STEMI, ST-segment-elevation myocardial infarction. BP-SES vs DP-EES in Diabetes Mellitus treatment with DP-EES. The other 1633 (77%) patients without diabetes mellitus were randomly assigned to BP-SES (n=806; 1198 lesions) or DP-EES (n=827; 1214 lesions; Figure 1 ).
As shown in Table I in the Data Supplement, higher risk profile, in terms of cardiac risk factors, was associated with diabetic status. However, baseline clinical features were well balanced between the 2 treatment arms (BP-SES or DP-EES) in both diabetic and nondiabetic patients ( Table 1) . Most of patients with diabetes mellitus were on oral hypoglycemic agents. Insulin-dependent diabetes mellitus was present in 89 (34.6%) patients allocated to BP-SES and 71(31%) patients allocated to DP-EES. Almost half of the diabetic patients presented with an acute coronary syndrome.
There was a similar distribution between the 2 treatment arms with regard to the target vessel, number of treated lesions, and lesion characteristics, such as restenosis or chronic total occlusion, as shown in Table 2 . Angiographic characteristics of diabetic versus nondiabetic subjects are shown in Table II in the Data Supplement.
Diabetic status was associated with a higher rate of prescription of cardiac medications (antiplatelet agents, statins, angiotensin-converting enzyme inhibitors, and β-blockers) at baseline. As it relates to prescription of P2Y 12 inhibitors, diabetic patients were more likely on clopidogrel rather than on prasugrel ≤1 year follow-up (Table III in the  Data Supplement) . However, as shown in Table IV in the Data Supplement, both treatment arms in each population (with and without diabetes mellitus) were largely comparable. Low rates in usage of glycoprotein IIb/IIIa inhibitors were reported in the entire diabetic population. A high adherence to dual antiplatelet therapy was recorded ≤12 months without differences between groups. Data expressed as n (%), or mean±SD. P value testing diabetic vs nondiabetic patients using Fisher exact tests or unpaired t tests. Interaction P value from logistic regressions or general linear models, testing for the interaction between diabetic status and randomized stent. BP-SES indicates biodegradable polymer sirolimuseluting stent; CABG, coronary artery bypass graft surgery; CAD, coronary artery disease; DP-EES, durable polymer everolimus-eluting stent; GFR, glomerular filtration rate; MI, myocardial infarction; PCI, percutaneous coronary intervention; and TIA, transient ischemic attack. *n=256; †n=229; ‡n=61; §n=51; ‖n=237; ¶n=199; #n=210; **n=228; † †n=220; ‡ ‡n=178; § §n=803; ‖‖n=805; ¶ ¶n=801; ##n=771; ***n=653; † † †n=820; ‡ ‡ ‡n=825; § § §n=826; ‖‖‖n=775; ¶ ¶ ¶n=667. 
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Clinical Outcomes According to Diabetic Status
As summarized in Table 3 and shown in Figure 2, otherwise P values from mixed models for the per-lesion analyses, accounting for lesions nested within patients: general linear mixed models for continuous variables, generalized linear mixed models for counts n. Interaction P value testing for the interaction between diabetic status and randomized stent. Long lesion: total stent length >20 mm; smallvessel: minimum stent diameter <2.75 mm. BP-SES indicates biodegradable polymer sirolimus-eluting stent; CABG, coronary artery bypass graft surgery; DP-EES, durable polymer everolimus-eluting stent; IABP, intra-aortic balloon pump; and TIMI, thrombolysis in myocardial infarction.
‡P value for response stenting vs not stented. §P value for any nonrandomized stent implanted per patient. ‖n=376; ¶n=395 #n=323; **n=1196; † †n=1195; ‡ ‡n=1141; § §n=1189; ‖‖n=1213; ¶ ¶n=1209; ##n=1211; ***n=1160; † † †n=1158. 
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Clinically indicated TLR (5.6% versus 2.1%; HR, 2.63; 95% CI, 1.58-4.39; P<0.001) and target-vessel revascularization (6.0% versus 3.1%; HR, 1.92; 95% CI, 1.21-3.05; P=0.006) were more common among diabetic patients.
Rates of definite ST (both late and early-to-late ST) were significantly higher in patients with diabetes mellitus compared with nondiabetic patients (Table 4) .
Clinical Outcomes According to Stent Type
Irrespective of the increased event rates for the primary end point among patients with diabetes mellitus, both stent groups resulted in similar outcomes in the head-to-head comparison in the subgroup of diabetic and nondiabetic patients. As reported in Table 5 and displayed in Figure 2 , target lesion failure occurred in 27 (10.9%) diabetic patients treated with BP-SES and 21 (9.3%) patients treated with DP-EES (HR, 1.19; 95% CI, 0.67-2.10; P=0.56). The individual components of the primary end point were numerically higher in diabetic patients treated with BP-SES; however, the difference with the DP-EES group did not reach statistical significance: rates of cardiac death were 3.6% in the BP-SES group and 3.1% in the DP-EES group (HR, 1.18; 95% CI, 0.44-3.16; P=0.74); rates of target-vessel myocardial infarction were 4.9% and 2.7% (HR, 1.83; 95% CI, 0.69-4.88; P=0. 23) , and rates of clinically indicated TLR were 6.6% in the BP-SES groups versus 4.5% in the DP-EES group (HR, 1.49; 95% CI, 0.68-3.28; P=0.32), respectively. Although the absolute number of definite ST was higher in diabetic patients treated with BP-SES, no significant differences were recorded between the study arms at different time points.
Among nondiabetic patients, the primary end point occurred in 42 (5.3%) subjects allocated to BP-SES and 49 (6.0%) allocated to DP-EES (HR, 0.88; 95% CI, 0.58-1.33; P=0.55). Rates of cardiac death were 1.4% in the BP-SES group and 1.8% in the DP-EES group (HR, 0.76; 95% CI, 0.35-1.65; P=0.48); rates of target-vessel myocardial infarction were 2.3% and 3.1% (HR, 0.74; 95% CI, 0.40-1.36; P=0.33), respectively, and rates of clinically indicated TLR were 2.48% in the BP-SES groups versus 1.9% in the DP-EES group (HR, 1.31; 95% CI, 0.67-2.58; P=0.43). No differences in rates of definite ST at different time points were reported between treatment arms Table 6 .
Discussion
The present prespecified subgroup analysis according to diabetic status from the BIOSCIENCE trial has the following main findings: (1) compared with nondiabetic patients and despite high compliance with guideline-guided medical care, clinical outcomes continue to be worse in diabetic patients 
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undergoing coronary stenting; (2) no significant differences in the rate of the primary end point and its individual components were observed among diabetic patients allocated to BP-SES or DP-EES at 1 year follow-up; and (3) the risk of stent thrombosis was similar among diabetic patients treated with BP-SES and DP-EES throughout 1 year. Diabetic status affects the short-and long-term outcomes after PCI through several pathophysiological mechanisms: hyperglycemia and insulin resistance accelerate atherosclerosis and promote endothelial dysfunction, impair vasodilation, exaggerate neointimal hyperplasia, and abnormal platelet function. 13 Furthermore, the proinflammatory environment of diabetes mellitus enhances the vasculoproliferative cascade in response to stent-mediated arterial injury.
14 As consequence, patients with diabetes mellitus experience both a higher rate of recurrent ischemic events related to progression of new atherosclerotic lesions and worse clinical outcomes for stent-related complications (restenosis and thrombosis). 15 Indeed, the increase in target lesion failure in diabetic subjects included in our analysis was driven by both higher rates of repeat revascularization and occurrence of major hard events, including cardiac death and myocardial infarction.
Current evidence supports the use of DP-EES in patients with diabetes mellitus undergoing PCI. Compared with bare-metal stents, the number needed to treat to prevent a revascularization procedure was 13.4 with the use of DP-EES, whereas the 2-year risk of stent thrombosis for DP-EES was about a third to half of that after implantation of another DES. 16 Nevertheless, our study shows significantly higher rates of adverse events in a broad diabetic population on a background of evidence-based medical management. This finding highlights the continued need of pursuing more effective devices for this high-risk population.
Evolving stent technology could help to overcome these limitations by mitigating the device-related risk of recurrent events. Polymers are essential for drug elution from the DES surface; however, persistence of polymer remnants within the arterial wall beyond the time of drug release may elicit a chronic inflammatory stimulus resulting in impaired vessel healing that has been related to adverse clinical events. 17 The safety concerns intrinsic to early generation DES have been largely resolved by refinements of stent geometry and composition. Indeed, new-generation DES with thin strut, cobalt-or platinum-chromium platforms, durable and biodegradable biocompatible polymers have significantly lowered the risk of ST, both early and late compared with early generation DES. [18] [19] [20] Against this background, BP-DES offer the potential advantage to avoid the persistent arterial injury through biodegradation of the polymer. 21 First generation BP-DES (biolimus-eluting) with a thick strut stainless steel platform showed comparable clinical outcomes compared with first generation DES (sirolimus-eluting) and a favorable safety profile with lower rates of stent thrombosis ≤3 years of follow-up in patients with diabetes mellitus. 6 Factors other than polymer can affect stent thrombogenicity and ultimately the risk of ST: thick-strutted stents have been shown to result in higher rates of luminal flow disruption and thrombus formation on the surface compared with thin-strutted devices in experimental models. 22 The geometry of second generation BP-DES has been improved with a significant reduction of 
strut thickness compared with new-generation DP-DES (60 versus 81 μm, respectively).
The Orsiro stent is a new-generation BP-DES combining an ultrathin cobalt-chromium platform with an asymmetrical biodegradable polymer matrix that elutes sirolimus during 12 to 14 weeks. Higher thickness on the abluminal side of the matrix (7.5 μm) ensures a greater drug release compared with the luminal side (3.5 μm). Biodegradation of the polymer is completed in 12 to 24 months. Subsequently, the passive silicon carbide coating acts as a diffusion barrier between vessel wall and lumen. In the randomized Study of the Orsiro Drug Eluting Stent System (BIOFLOW II) trial, BP-SES was shown to be noninferior to DP-EES in terms of the primary angiographic end point in-stent late lumen loss at 9 months (0.10±0.321 mm versus 0.11±0.29 mm; P noninferiority <0.0001, respectively). Optical coherence tomography and intravascular ultrasound performed in a subgroup of patients at the time of the angiographic follow-up showed adequate stent strut coverage in both groups similar neointimal thickness without differences in terms of uncovered or malapposed struts. Assessment of clinical outcomes ≤1 year showed similar rates of TLF (defined as the composite of cardiac death, targetvessel myocardial infarction, coronary artery bypass grafting, or clinically driven TLR; BP-SES 6.5% versus DP-EES 8.0%; Number of first events (cumulative incidences using Kaplan-Meier method %) are reported. Hazard ratios (95% CI) are estimated using the Mantel-Cox method with 2-sided P values from Log-rank test. Interaction P value test for effect modification of the difference between the diabetics vs nondiabetics because of the randomized stent. All events were censored beyond 365 d. Continuity corrected rate ratios with Fisher exact test for zero outcomes. BARC indicates Bleeding Academic Research Consortium; BP-SES, biodegradable polymer sirolimus-eluting stents; CI, confidence interval; DP-EES, durable polymer everolimus-eluting stents; MI, myocardial infarction; TLR, target lesion revascularization; and TVR, target-vessel revascularization.
*Primary end point, defined as the composite of cardiac death, target-vessel Q wave or non-Q wave MI, clinically indicated TLR, and clinically indicated surgical TVR. †Defined as the composite of cardiac death, any Q wave or non-Q wave MI, and any TVR. ‡Patient oriented composite end point. §Includes ischemic stroke, intracerebral hemorrhage, and unclear cause of cerebrovascular events.
HR, 0.82; 95% CI, 0.40-1.68; P=0.58). 23 These findings have been corroborated in the large scale BIOSCIENCE trial in a population including patients with stable coronary artery disease or acute coronary syndromes and minimal exclusion criteria. BP-SES was found noninferior to DP-EES for the composite end point target lesion failure at 12 months (6.5% versus 6.6%; 95% CI, 1.97%; P noninferiority <0.0004). 7 In the present subgroup analysis, diabetic patients experienced a higher rate of target lesion failure compared with nondiabetic subjects. However, no significant differences in the occurrence of the primary end point and its individual components were observed among patients with diabetes mellitus allocated to BP-SES or DP-EES treatment. This finding is consistent with the results observed in the overall trial population and supports the safety and efficacy of the new BP-SES even in the high-risk diabetic subgroup.
Furthermore, the absence of significant differences in the rate of stent thrombosis at 1 year follow-up between the study groups is noteworthy. We acknowledge that previous studies have questioned the safety and efficacy of DP-EES compared with paclitaxel-eluting stents in patients with diabetes mellitus. 22 Differential effects of diabetic status on antirestenotic properties of rapamycin and paclitaxel have been advocated as main drivers of higher rates of stent thrombosis in diabetic patients treated with EES. However, several other factors, such as stent design (strut thickness) and polymer features (biodegradable or durable), could play a pivotal role in the outcomes of different DES in diabetic population.
The present analysis has several limitations. First, as per design of the main trial, randomization was not stratified by diabetic status. Second, diabetic status was assessed on the basis of clinical history of patients, so we missed in our analysis patients who discovered diabetes mellitus during hospitalization or follow-up. Furthermore, levels of glycohemoglobin were not available for the entire diabetic population. Third, although prespecified, this subgroup analysis was not powered for the reported end points and its results are only hypothesis generating. Furthermore, current findings are limited at 1 year follow-up whereas potential differences between the compared devices could emerge later, when drug elution and polymer degradation are completed. Because debris resulting from coating degradation could trigger an inflammatory tissue response, a longer follow-up and larger population are needed to definitely compare the safety and efficacy profiles of the devices. Fourth, high adherence to dual antiplatelet therapy and concomitant cardiac medications was recorded for both study arms: >80% of patients complied with any dual antiplatelet therapy, and a large proportion of them were also prescribed ACE-inhibitors, β-blockers and statins at 12-month follow-up. Adequate secondary prevention is essential for diabetic patients as many adverse events are patient-related rather than stent-related. Fifth, we did not stratify the analysis according to insulindependent or noninsulin-dependent diabetes mellitus because of the limited total number of diabetic patients in the trial.
Conclusions
Despite significant improvements in the level of medical care, diabetic status remains associated with higher mortality and risk of recurrent adverse events, thus, addressing the need for an ideal coronary stent. In the prespecified subgroup analysis of the Number of first events (cumulative incidences using Kaplan-Meier method %) are reported. Hazard ratios are estimated using Cox regressions with 2-sided P values from χ 2 tests. Possible stent thrombosis cannot occur by definition within 30 d. Landmark used at 30 d for >30 d to 12 mo analyses. Interaction P value test for effect modification of the difference between the diabetics vs nondiabetics because of the randomized stent (in case of definite stent thrombosis 0 to 30 d using an approximate test). BP-SES indicates biodegradable polymer sirolimus-eluting stents; CI, confidence interval; and DP-EES, durable polymer everolimus-eluting stents.
